Our results strongly suggest that future studies should determine the role of RelB in identifying CLL patients that would be sensitive to inhibition of non-canonical NF-κB signalling as a means to developing personalized therapies. The gene discussed is NFKB1; the disease is B-cell chronic lymphocytic leukemia.